Maintaining cognitive function in Alzheimer disease: How effective are current treatments?

Alzheimer Disease and Associated Disorders

Volumn 15, Issue SUPPL. 1, 2001, Pages

  Tariot, P N ^a  

^a Monroe Community Hospital   (United States)

Author keywords

ADAS cog mem; Allosteric modulation; Alzheimer disease; Cognitive function; Galantamine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NICOTINIC RECEPTOR; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; HUMAN; NEUROMODULATION; NEUROTRANSMISSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 0034876669     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200108001-00005     Document Type: Conference Paper

References (47)

1. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function
2. The treatment of Alzheimer's disease
3. The cholinergic hypothesis of geriatric memory dysfunction
4. Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers
5. Galantamine: Therapeutic effects beyond cognition
6. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine
7. Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease
8. Galantamine an acetycholinesterase inhibitor that modulates nicotinic receptors: Effects on the course of Alzheimer's disease
9. Neuropsychological assessment
10. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician
11. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia
12. Language impairment and rate of cognitive decline in Alzheimer's disease
13. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group
14. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
15. Cognition
16. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group
17. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
18. Long-term tacrine effects
19. Nicotinic acetylcholine involvement in cognitive function in animals
20. Galantamine alleviates caregiver burden in Alzheimer's disease: A 12-month study
21. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease
22. Galantamine produces long-term cognitive and functional benefits in patients with Alzheimer's disease
23. The ability of the dementia rating scale to predict everyday functioning
24. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
25. An evaluation of the long-term efficacy of donepezil in patients from a phase III clinical extension trial
26. The cognitive and functional benefits of galantamine: A 12-month study in Alzheimer's disease
27. Galantamine in Alzheimer's disease - A 6-month, randomized, placebo-controlled trial with a 6-month extension
28. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open-label extension study
29. A new rating scale for Alzheimer's disease
30. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease
31. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands
32. Long-term administration of oral physostigmine in Alzheimer's disease
33. A longitudinal study of Alzheimer's disease: Measurement, rate and predictors of cognitive deterioration
34. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease
35. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
36. 12-Month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: Two randomized, placebo-controlled studies
37. A correlation between cognitive performance and daily functioning in elderly people
38. The long-term cognitive benefits of galantamine treatment in patients with Alzheimer's disease
39. First international pharmacoeconomic conference on Alzheimer's disease: Report and summary
40. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group
41. Predictive validity of factors influencing the institutionalization of elderly people with psychogeriatric disorders
42. Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate Alzheimer's disease
43. Outcome measures in Alzheimer's disease: Do they go far enough?